Clinical pregnancy rate · ovulation induction in polycystic ovarian syndrome
Antioestrogen may leads to higher clinical pregnancy rate compared with placebo (low certainty).
1 finding from 1 review
Multiple pregnancy rate ‐ not reported · ovulation induction in polycystic ovarian syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ovarian hyperstimulation syndrome (OHSS) ‐ not reported · ovulation induction in polycystic ovarian syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Live birth · women with subfertility
Low‐dose aspirin showed no clear difference in live birth compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Clinical pregnancy · women with subfertility
Low‐dose aspirin showed no clear difference in clinical pregnancy compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Multiple pregnancy · women with subfertility
Low‐dose aspirin showed no clear difference in multiple pregnancy (on ultrasound) compared with placebo or no treatment (low certainty).
1 finding from 1 review
Miscarriage · women with subfertility
Low‐dose aspirin showed no clear difference in miscarriage rate per woman compared with placebo or no treatment (low certainty).
1 finding from 1 review
Ectopic pregnancy · women with subfertility
It is very uncertain whether low‐dose aspirin changes ectopic pregnancy compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Vaginal bleeding · women with subfertility
It is very uncertain whether low‐dose aspirin changes vaginal bleeding compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Other adverse events · women with subfertility
The review found no eligible studies for this question.
1 finding from 1 review
Vasomotor symptoms (all doses) · postmenopausal women with vasomotor symptoms
Tibolone probably leads to lower vasomotor symptoms (all doses) compared with placebo (moderate certainty).
1 finding from 1 review
Endometrial cancer · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes endometrial cancer (all doses) compared with placebo (very low certainty).
1 finding from 1 review
Breast cancer; women without previous breast cancer (all doses) · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes breast cancer; women without previous breast cancer (all doses) compared with placebo (very low certainty).
1 finding from 1 review
Unscheduled bleeding (all doses) · postmenopausal women with or without vasomotor symptoms
Tibolone probably leads to higher unscheduled bleeding (all doses) compared with placebo (moderate certainty).
1 finding from 1 review
Venous thromboembolic events · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes venous thromboembolic events (clinical evaluation) all doses compared with placebo (very low certainty).
1 finding from 1 review
Cardiovascular events · postmenopausal women with or without vasomotor symptoms
1 finding from 1 review
Cerebrovascular event (all doses) · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes cerebrovascular events (all doses) compared with placebo (very low certainty).
1 finding from 1 review
Mortality from any cause (all doses) · postmenopausal women with or without vasomotor symptoms
Tibolone showed no clear difference in mortality from any cause (all doses) compared with placebo (low certainty).
1 finding from 1 review
Vasomotor SymptomsFrequency of hot flushes measured in a diary (daily) · women with menopausal symptoms
1 finding from 1 review
Vasomotor SymptomsSeverity of hot flushes measured in a diary (daily) · women with menopausal symptoms
1 finding from 1 review